Autonomous artificial intelligence increases screening and follow-up for diabetic retinopathy in youth: the ACCESS randomized control trial.
T Y Alvin LiuRoomasa ChannaT Y Alvin LiuAnum ZehraLee BrombergerDhruva PatelAjaykarthik AnanthakrishnanElizabeth A BrownLaura M PrichettHarold P LehmannMichael D AbramoffPublished in: Nature communications (2024)
Diabetic retinopathy can be prevented with screening and early detection. We hypothesized that autonomous artificial intelligence (AI) diabetic eye exams at the point-of-care would increase diabetic eye exam completion rates in a racially and ethnically diverse youth population. AI for Children's diabetiC Eye ExamS (NCT05131451) is a parallel randomized controlled trial that randomized youth (ages 8-21 years) with type 1 and type 2 diabetes to intervention (autonomous artificial intelligence diabetic eye exam at the point of care), or control (scripted eye care provider referral and education) in an academic pediatric diabetes center. The primary outcome was diabetic eye exam completion rate within 6 months. The secondary outcome was the proportion of participants who completed follow-through with an eye care provider if deemed appropriate. Diabetic eye exam completion rate was significantly higher (100%, 95%CI: 95.5%, 100%) in the intervention group (n = 81) than the control group (n = 83) (22%, 95%CI: 14.2%, 32.4%)(p < 0.001). In the intervention arm, 25/81 participants had an abnormal result, of whom 64% (16/25) completed follow-through with an eye care provider, compared to 22% in the control arm (p < 0.001). Autonomous AI increases diabetic eye exam completion rates in youth with diabetes.
Keyphrases
- artificial intelligence
- type diabetes
- diabetic retinopathy
- randomized controlled trial
- machine learning
- big data
- deep learning
- healthcare
- wound healing
- primary care
- mental health
- physical activity
- cardiovascular disease
- young adults
- palliative care
- glycemic control
- quality improvement
- optical coherence tomography
- study protocol
- double blind
- insulin resistance
- pain management
- placebo controlled
- clinical trial
- phase iii
- affordable care act